Impact of the Martin/Hopkins modified equation for estimating LDL-C on lipid target attainment in a high risk patient population.


Journal

Clinical biochemistry
ISSN: 1873-2933
Titre abrégé: Clin Biochem
Pays: United States
ID NLM: 0133660

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 03 10 2019
revised: 27 11 2019
accepted: 03 12 2019
pubmed: 18 12 2019
medline: 18 2 2020
entrez: 18 12 2019
Statut: ppublish

Résumé

To evaluate the Martin/Hopkins equation for estimating LDL-C as target in a population composed of high cardiac risk patients. Lipid profile data from patients with TG ≤ 4.52 mmol/L (<400 mg/dl) were used. The high cardiac risk group (N 4150) consisted of patients over 40 years of age that had an A1C level of 6.5% or above and patients with a history of atherosclerotic cardiovascular disease (ASCVD). Comparisons were made between the Martin/Hopkins formula (MH-LDL-C), the Friedewald formula (F-LDL-C), Non-HDL-C and ApoB. Higher LDL-C values (0.15 mmol/L or 7.3%) were obtained using MH-LDL-C compared to the F-LDL-C. The % within target (%WT) values for F-LDL-C, MH-LDL-C, Non-HDL-C and ApoB were similar when TG levels were ≤ 1.5 mmol/L with a high degree of concordance as measured by the kappa statistic. When compared to F-LDL-C, Non-HDL-C and ApoB showed a profound decrease in the WT value as TG levels increased from normal (67.7%) to intermediate (39.1%) and high levels (20.8%). MH-LDL-C showed an attenuated decrease in the WT value as TG increased from normal (61.4%) intermediate (43.4%) and high levels (32.7%). Concordance with the alternate target parameters was higher for MH-LDL-C than for F-LDL-C when triglycerides levels were increased. The Martin/Hopkins modified equation for estimating LDL-C is a significant improvement on the decade's old Friedewald formula; however it remains an imperfect tool to estimate the atherogenic load in patients with high TG levels.

Identifiants

pubmed: 31843663
pii: S0009-9120(19)31076-8
doi: 10.1016/j.clinbiochem.2019.12.002
pii:
doi:

Substances chimiques

Cholesterol, LDL 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

35-37

Informations de copyright

Copyright © 2019 The Canadian Society of Clinical Chemists. All rights reserved.

Auteurs

Louis-Jacques Cartier (LJ)

The Moncton Hospital, Horizon Health Network, NB, Canada. Electronic address: Dr.Louis.Cartier@horizonnb.ca.

Simon St-Coeur (S)

The Moncton Hospital, Horizon Health Network, NB, Canada.

Alex Robin (A)

The Moncton Hospital, Horizon Health Network, NB, Canada.

Mathieu Lagace (M)

The Moncton Hospital, Horizon Health Network, NB, Canada.

Pierre Douville (P)

Centre Hospitalier Universitaire de Québec, Québec, QC, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH